The liver-heart axis in patients with severe obesity : The association between liver fibrosis and chronic myocardial injury may be explained by shared risk factors of cardiovascular disease
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Severe obesity is associated with increased risk of non-alcoholic fatty liver disease and cardiovascular disease. We hypothesized that liver fibrosis as quantified by the Enhanced Liver Fibrosis (ELF) test would be predictive of myocardial injury and fibrosis, expressed by higher concentrations of cardiac troponin T and I measured by high-sensitivity assays (hs-cTnT and hs-cTnI, respectively).
MATERIAL AND METHODS: We performed cross-sectional analyses of baseline data from 136 patients (mean age 45 years, 38 % male) with severe obesity participating in the non-randomized clinical trial Prevention of Coronary Heart Disease in Morbidly Obese Patients (ClinicalTrials.gov NCT00626964). Associations between ELF scores, hs-cTnT, and hs-cTnI concentrations were assessed using linear regression analysis.
RESULTS: ELF scores were associated with hs-cTnT in the unadjusted model (B 0.381, 95 % Confidence Interval [CI] 0.247, 0.514), but the association was attenuated upon adjustment for potential confounders (B -0.031, 95 % CI -0.155, 0.093). Similarly, for hs-cTnI, an observed association with ELF scores in the unadjusted model was attenuated upon adjustment for potential confounders ((B 0.432, 95 % CI 0.179, 0.685) and (B 0.069, 95 % CI -0.230, 0.367), respectively). Age, sex, hypertension, and estimated glomerular filtration rate were amongst the shared predictors of ELF score, hs-cTnT, and hs-cTnI that provided the univariable models with the highest R-squared and lowest Akaike Information Criterion values.
CONCLUSIONS: Contrary to our hypothesis, ELF score did not predict myocardial injury and fibrosis, but we rather demonstrated an association between liver fibrosis and myocardial injury and fibrosis may be explained by shared risk factors of cardiovascular disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:123 |
|---|---|
| Enthalten in: |
Clinical biochemistry - 123(2024) vom: 22. Jan., Seite 110688 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Young, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 23.01.2024 Date Revised 23.01.2024 published: Print-Electronic ClinicalTrials.gov: NCT00626964 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clinbiochem.2023.110688 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364871075 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364871075 | ||
| 003 | DE-627 | ||
| 005 | 20240124232002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinbiochem.2023.110688 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM364871075 | ||
| 035 | |a (NLM)37995847 | ||
| 035 | |a (PII)S0009-9120(23)00216-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Young, J |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The liver-heart axis in patients with severe obesity |b The association between liver fibrosis and chronic myocardial injury may be explained by shared risk factors of cardiovascular disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00626964 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Severe obesity is associated with increased risk of non-alcoholic fatty liver disease and cardiovascular disease. We hypothesized that liver fibrosis as quantified by the Enhanced Liver Fibrosis (ELF) test would be predictive of myocardial injury and fibrosis, expressed by higher concentrations of cardiac troponin T and I measured by high-sensitivity assays (hs-cTnT and hs-cTnI, respectively) | ||
| 520 | |a MATERIAL AND METHODS: We performed cross-sectional analyses of baseline data from 136 patients (mean age 45 years, 38 % male) with severe obesity participating in the non-randomized clinical trial Prevention of Coronary Heart Disease in Morbidly Obese Patients (ClinicalTrials.gov NCT00626964). Associations between ELF scores, hs-cTnT, and hs-cTnI concentrations were assessed using linear regression analysis | ||
| 520 | |a RESULTS: ELF scores were associated with hs-cTnT in the unadjusted model (B 0.381, 95 % Confidence Interval [CI] 0.247, 0.514), but the association was attenuated upon adjustment for potential confounders (B -0.031, 95 % CI -0.155, 0.093). Similarly, for hs-cTnI, an observed association with ELF scores in the unadjusted model was attenuated upon adjustment for potential confounders ((B 0.432, 95 % CI 0.179, 0.685) and (B 0.069, 95 % CI -0.230, 0.367), respectively). Age, sex, hypertension, and estimated glomerular filtration rate were amongst the shared predictors of ELF score, hs-cTnT, and hs-cTnI that provided the univariable models with the highest R-squared and lowest Akaike Information Criterion values | ||
| 520 | |a CONCLUSIONS: Contrary to our hypothesis, ELF score did not predict myocardial injury and fibrosis, but we rather demonstrated an association between liver fibrosis and myocardial injury and fibrosis may be explained by shared risk factors of cardiovascular disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiac fibrosis | |
| 650 | 4 | |a Cardiac troponin | |
| 650 | 4 | |a Enhanced Liver Fibrosis test | |
| 650 | 4 | |a Liver fibrosis | |
| 650 | 4 | |a Myocardial injury | |
| 650 | 4 | |a NT-proBNP | |
| 650 | 4 | |a Severe obesity | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Troponin T |2 NLM | |
| 700 | 1 | |a Seeberg, K A |e verfasserin |4 aut | |
| 700 | 1 | |a Aakre, K M |e verfasserin |4 aut | |
| 700 | 1 | |a Borgeraas, H |e verfasserin |4 aut | |
| 700 | 1 | |a Nordstrand, N |e verfasserin |4 aut | |
| 700 | 1 | |a Wisløff, T |e verfasserin |4 aut | |
| 700 | 1 | |a Hjelmesæth, J |e verfasserin |4 aut | |
| 700 | 1 | |a Omland, T |e verfasserin |4 aut | |
| 700 | 1 | |a Hertel, J K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical biochemistry |d 1970 |g 123(2024) vom: 22. Jan., Seite 110688 |w (DE-627)NLM000001988 |x 1873-2933 |7 nnns |
| 773 | 1 | 8 | |g volume:123 |g year:2024 |g day:22 |g month:01 |g pages:110688 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinbiochem.2023.110688 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 123 |j 2024 |b 22 |c 01 |h 110688 | ||